These findings suggest that PD-1 targeting released the immune-suppressive regulation and restored the tumor-specific cytotoxicity of either cytotoxic T lymphocytes or NK cells, which are the cellular components mediating the effects of the PD-1 blockade [55,56]. Here, PDCD1 is linked to neoplasm.